<DOC>
	<DOC>NCT00569803</DOC>
	<brief_summary>Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects</brief_summary>
	<brief_title>Subcutaneous Pharmacokinetics of Belatacept</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men and women ages 18 to 65 years old Subjects must weigh less than or equal to 100 kg Inability to tolerate injections or IV infusions autoimmune disorders TB herpes HCV HBV HIV bacterial or viral infection history of cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>